AKT1 and neoplasm: LILRB4 recruited Src homology 2 domain-containing inositol phosphatase 1 (SHIP1), inhibiting B-cell receptor (BCR)-dependent AKT signaling and thereby driving tumor progression (Figure 3C) 301.